Tim Cortese

1 week ago | cancernetwork.com | Ariana Pelosci |Tim Cortese

The FDA has approved nivolumab (Opdivo) plus ipilimumab (Yervoy) for patients with unresectable or metastatic hepatocellular carcinoma, according to a press release from the agency.1The approval was based on results from the phase 3 CheckMate 9DW trial (NCT04039607) assessing nivolumab/ipilimumab vs lenvatinib (Lenvima) or sorafenib (Nexavar).

2 weeks ago | cancernetwork.com | Tim Cortese

“Whatever your situation, I wish I could sit with you and talk about what’s been going on for you and how you’ve been coping, and help you find the kind of support that’s right for you. That’s the way I would like to do it. But since that’s impossible, I’ve tried through the chapters of this book to talk with you as I would if you were in my office and we were talking face-to-face about your illness or that of your loved one and about the problems you’ve had to deal with along the way.”1Jimmie C.

2 weeks ago | cancernetwork.com | Tim Cortese

The adoptive transfer of unselected autologous tumor-infiltrating lymphocytes (TILs) selected for neoantigen recognition plus pembrolizumab (Keytruda) treatment strategy surpassed trial design parameters for those with colorectal cancer and demonstrated it could become a cell-based treatment option in a patient population not generally expected to respond to immunotherapy, according to results from a phase 2 study (NCT01174121) published in Nature Medicine.

2 weeks ago | cancernetwork.com | Tim Cortese

The FDA has approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC), according to a press release from the FDA.1 Addiitonally, the FDA converted the accelerated approval for single-agent nivolumab to a normal approval for adult and pediatric patients with MSI-H or dMMR metastatic CRC who progressed on fluoropyrimidine,...

2 weeks ago | cancernetwork.com | Tim Cortese

Palbociclib (Ibrance) did not show statistically significant survival improvements in patients with hormone receptor (HR)–positive, HER2-negative breast cancer with residual disease and high relapse risk after taxane-based neoadjuvant chemotherapy, according to data from the phase 3 PENELOPE-B trial (NCT01864746) published in Annals of Oncology.1 The trial also found, in exploratory analyses, a trend towards improved invasive disease-free survival (DFS) with palbociclib in patients with...